Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.

Isik, UlasKostek, OsmanDemiray, GokcenDirican, AhmetSimsek, MelihBuyuksimsek, MahmutUcar, Gokhan2024-06-122024-06-1220190732-183X1527-7755https://doi.org/10.1200/JCO.2019.37.15_suppl.e16075https://hdl.handle.net/20.500.14551/25939Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, IL[Abstract Not Available]en10.1200/JCO.2019.37.15_suppl.e16075info:eu-repo/semantics/closedAccess[No Keywords]Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.Conference Object3715Q1WOS:000487345801503